---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-26-002429"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:18:20.376528+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tonix prelim 2025: net loss $118.9M vs $130.0M; cash $207.6M funds ops into Q1 2027

## Summary
- Cash & equivalents $207.6M at Dec 31, 2025; 12.79M shares outstanding as of Jan 30, 2026.
- Net loss $118.9M (2025) vs $130.0M (2024); net cash used in operations $99.0M vs $60.9M.
- Net product revenue $13.1M (2025) vs $10.1M (2024); Zembrace/Tosymra $11.7M vs $10.1M.
- TONMYA launch Nov 17, 2025 generated $1.4M from launch to Dec 31, 2025.
- Capital expenditures $3.4M in 2025 vs $0.1M in 2024; cash expected to fund ops into Q1 2027.

## SEC filing metadata
- accession: 0001999371-26-002429
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937126002429/0001999371-26-002429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937126002429/tonix-8k_020326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-26-002429
- JSON: https://secwatch.observer/filing/0001999371-26-002429.json
- Plain text: https://secwatch.observer/filing/0001999371-26-002429.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.